European Medicines Agency

EUROPEAN MEDICINES AGENCY NEWSROOM (8 press releases)

Advanced Filtering & Sorting Options:

Sandoz’s EGALITY trial results: equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 met

PRESS RELEASE -- 8, July 2016

The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the confirmatory clinical safety and efficacy study compares originator etanercept to a biosimilar candidate … Read the full press release

Roche’s Marketing Authorisation Application and Biologics License Application for OCREVUS accepted by EMA and FDA

PRESS RELEASE -- 29, June 2016

OCREVUS is the first investigational medicine seeking marketing authorisation for both relapsing and primary progressive multiple sclerosis (MS) FDA grants Priority Review Designation for OCREVUS Biologics License Application (BLA) BASEL, 29-Jun-2016 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced … Read the full press release

European Medicines Agency accepted Sandoz’s Marketing Authorization Application for biosimilar to Roche’s EU-licensed MabThera®

PRESS RELEASE -- 27, May 2016

Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product’s label Sandoz’ submission includes data from multiple clinical trials with over 800 patients … Read the full press release

AstraZeneca announces positive CHMP opinion recommending the approval of new antibiotic, CAZ AVI

PRESS RELEASE -- 2, May 2016

LONDON, 02-May-2016 — /EuropaWire/ — AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending the approval of a new antibiotic, CAZ AVI 2g/0.5g powder. CAZ … Read the full press release

Boehringer Ingelheim’s Interim Phase III Data: 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated

PRESS RELEASE -- 8, April 2016

• A single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated • Results based on analyses of high-risk patients from RE-VERSE AD™ study • Data presented at ACC 2016 Scientific Session and Expo … Read the full press release

Christoph Krähenbühl to speak at Systech UNIQUITY Conference in Amsterdam

PRESS RELEASE -- 30, March 2016

SUBJECT: REGULATORY LANDSCAPE FOR PHARMA MANUFACTURERS AMSTERDAM, 30-Mar-2016 — /EuropaWire/ — Christoph Krähenbühl, senior director, 3C Excellis, will be a featured speaker at Systech International’s upcoming global conference in Amsterdam titled UNIQUITY Europe, 2016, focused on serialization, global brand protection … Read the full press release

Inno4Life Joins Systech’s UniSolve™ Partner Program

PRESS RELEASE -- 15, March 2016

Offers Integrated Serialization Equipment Solutions to the Global Pharma Industry BRUSSELS, 15-Mar-2016 — /EuropaWire/ — Systech International, a global leader in brand protection technologies, announces the addition of Inno4Life, an internationally recognized Original Equipment Manufacturer in Life Science equipment solutions, to its Unisolve™ partner … Read the full press release

The European Medicines Agency publishes guidance for the publication of clinical data

PRESS RELEASE -- 4, March 2016

Requirements for industry now available on submission of clinical data for publication LONDON, 04-Mar-2016 — /EuropaWire/ — The European Medicines Agency (EMA) has published detailed guidance for pharmaceutical companies on the requirements to comply with its policy on the publication of … Read the full press release